all

Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The trial met its primary endpoint, showing children who added investigational evinacumab to other lipid-lowering therapies reduced their low-density lipoprotein-cholesterol (LDL-C) by an average of 48% at week 24 of the study. Anne C.

Kowa Research Institute, Inc. has announced the decision to not continue its Phase 3 PROMINENT study. Read the press release. Kowa has indicated that full data will be shared at a future conference. 

Be sure to read the latest JCL Roundtable featuring Lauren Williams, RDN, Lynne T. Braun, PhD, CNP, FNLA, Joseph J. Saseen, PharmD, FNLA, and John R. Guyton, MD, FNLA discussing the importance of the lipidology team. 

Abstract